Ligand Pharmaceuticals Incorporated LGND 深 沪
等待开盘 04-03 09:30:00 美东时间
199.59
-0.030
-0.02%
华盛通- 最 高201.42
- 今 开197.54
- 成交量 22.19万股
- 最 低 194.6705
- 昨 收 199.62
- 总市值 39.80亿
- 52周最高 227.92
- 市盈率 静 32.55
- 换手率 1.11%
- 52周最低 98.89
- 委 比 -88.09%
- 总股本 1994.11万
- 历史最高 248.6071
- 量 比 0.96
- 振 幅 3.38%
- 历史最低 -19.8529
- 每 手 1
- 风险率 38.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
Ligand Pharmaceuticals has announced the appointment of Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development, reporting to Paul Hadden. Both bring extensive experience in healthcare investments and will focus on sourcing and transacting royalty financing opportunities. Lauren Hay has been promoted to Vice President of Portfolio Strategy and Investments, expanding her role to include growing and optimizing Li...
03-26 11:00
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $276
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $270 to $276.
03-24 23:14
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
B of A Securities Initiates Coverage On Ligand Pharmaceuticals with Buy Rating, Announces Price Target of $244
B of A Securities analyst Jason Zemansky initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy rating and announces Price Target of $244.
03-11 18:46
Ligand to Participate in March Investor Conferences
Ligand Pharmaceuticals announced that its senior management will participate in three upcoming investor conferences: the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026, the 38th Annual ROTH Conference in Dana Point, Calif., on March 23, 2026, and the Nordic-American Healthcare Conference (NAHC) in New York on March 25, 2026. Ligand management will host one-on-one meetings and present during these events to engage with in...
03-04 12:00
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
财报速睇 | Ligand Pharmaceuticals Incorporated 2025财年年度营收2.68亿美元，同比增长60.5%；归母净利润1.24亿美元，扭亏为盈
华盛资讯2月28日讯，Ligand Pharmaceuticals Incorporated公布2025财年年度业绩，公司年度营收2.68亿美元，同比增长60.5%，归母净利润1.24亿美元，扭亏为盈。
02-28 05:36
Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts
5 analysts have shared their evaluations of Ligand Pharmaceuticals (NASDAQ:LGND...
02-28 03:01
财报速睇 | Ligand Pharmaceuticals Incorporated 2025财年Q4营收0.60亿美元，同比增长39.4%；归母净利润0.45亿美元，扭亏为盈
华盛资讯2月26日讯，Ligand Pharmaceuticals Incorporated公布2025财年Q4业绩，公司Q4营收0.60亿美元，同比增长39.4%，归母净利润0.45亿美元，扭亏为盈。
02-26 20:49
